NCT00503243View on ClinicalTrials.gov

Safety and Efficacy of SPD476 (Mesalazine) Given Twice Daily (2.4 g/Day) vs SPD476 Given as a Single Dose (4.8 g/Day) in Subjects With Acute Mild to Moderate Ulcerative Colitis

PHASE3CompletedINTERVENTIONAL
Enrollment

280

Participants

Timeline

Start Date

September 30, 2003

Primary Completion Date

January 17, 2005

Study Completion Date

January 17, 2005

Conditions
Colitis, Ulcerative
Interventions
DRUG

Delayed and extended release mesalazine

Trial Locations (1)

Unknown

University of Pennsylvania, Philadelphia

Sponsors

Lead Sponsor

Shire
All Listed Sponsors
lead

Shire

INDUSTRY